Posted October 25, 2018 10:23:06 FDA approved three new antihypptric drugs in a preliminary review on Tuesday, as the agency continues to examine the efficacy and safety of two more drugs.
The FDA also approved the second of two new antifungal medications, Risperdal, which has a lower side effect profile than its predecessor.
The drugs, called Risporax and rituximab, are expected to be available in pharmacies by mid-November.